ArticleCancers2021

Durvalumab after Chemoradiotherapy for PD-L1 Expressing Inoperable Stage III NSCLC Leads to Significant Improvement of Local-Regional Control and Overall Survival in the Real-World Setting.

Julian Taugner et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.